What's the difference between Mounjaro and Ozempic? 🧐 Recent discussions have highlighted the FDA-approved GLP-1 medications Mounjaro (tirzepatide) and Ozempic (semaglutide) for their significant weight loss effects in addition to blood glucose control in type 2 diabetes. Mounjaro, acting as a dual GIP and GLP-1 receptor agonist, and Ozempic, a GLP-1 receptor agonist, have shown promise in managing obesity when combined with lifestyle changes. Notable differences in clinical effectiveness, side effects, and cost necessitate a tailored approach in selecting the appropriate medication for weight management. Mounjaro's rapid weight reduction capabilities, as evidenced in clinical trials, alongside Ozempic's benefits, underscore the need for informed decision-making in their off-label use for weight loss (Siddiqui & Doultani, 2023; Han et al., 2023). References: Siddiqui, T., & Doultani, P. R. (2023). Tirzepatide (Mounjaro) - a novel Pharmacotherapeutic Agent for Obesity. JPMA. The Journal of the Pakistan Medical Association. Tirzepatide (Mounjaro) - a novel Pharmacotherapeutic Agent for Obesity Han, S. H., Safeek, R., Ockerman, K. M., Trieu, N. S., Mars, P., Klenke, A., Furnas, H., & Sorice-Virk, S. (2023). Public Interest in the Off-Label Use of Glucagon-Like Peptide 1 Agonists (Ozempic) for Cosmetic Weight Loss: A Google Trends Analysis. Aesthetic Surgery Journal. Public Interest in the Off-Label Use of Glucagon-Like Peptide 1 Agonists (Ozempic) for Cosmetic Weight Loss: A Google Trends Analysis